Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders.

Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system and is integral to managing brain excitability. GABA concentrations vary according to age, gender, and brain region. Magnetic resonance spectroscopy (MRS), with editing or with localized 2-dimensional chemical shift methods, can measure GABA levels in vivo, ex vivo, or in vitro, particularly at ultra-high magnetic field strengths. Proton ((1)H) MRS studies have found reduced or abnormal GABA concentrations in several neuropsychiatric disorders, including epilepsy, anxiety disorders, major depression, and drug addiction. Disorders with low GABA levels may be treated by augmentation of GABAergic function, such as by medications that block the degradation or reuptake of GABA. Examples of such a rational therapeutic approach include anticonvulsants that elevate brain GABA levels and are effective for the treatment of epilepsy and anxiety disorder.

[1]  R. Ranaldi,et al.  Baclofen decreases methamphetamine self-administration in rats , 2002, Neuroreport.

[2]  Jullie W Pan,et al.  Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults , 2002, Neurology.

[3]  M. Cousins,et al.  GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. , 2002, Drug and alcohol dependence.

[4]  Mark Hallett,et al.  Impaired brain GABA in focal dystonia , 2002, Annals of neurology.

[5]  J. Brodie,et al.  Gamma‐vinyl GABA (GVG) blocks expression of the conditioned place preference response to heroin in rats , 2001, Synapse.

[6]  R Lufkin,et al.  Localized two‐dimensional shift correlated MR spectroscopy of human brain , 2001, Magnetic resonance in medicine.

[7]  P. Boesiger,et al.  Influence of pyridoxal 5′-phosphate alone and in combination with vigabatrin on brain GABA measured by 1H-NMR-spectroscopy , 2001, Brain Research Bulletin.

[8]  G F Mason,et al.  Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. , 2001, Archives of general psychiatry.

[9]  G. Incorpora,et al.  Neuropsychological assessment in children with absence epilepsy , 2001, Neurology.

[10]  R. Mattson,et al.  Topiramate Rapidly Raises Brain GABA in Epilepsy Patients , 2001, Epilepsia.

[11]  G. Bloch,et al.  Brain GABA editing without macromolecule contamination , 2001, Magnetic resonance in medicine.

[12]  A. Schousboe,et al.  Metabolic distinction between vesicular and cytosolic GABA in cultured GABAergic neurons using 13C magnetic resonance spectroscopy , 2001, Journal of neuroscience research.

[13]  J. Volpicelli,et al.  The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat , 2001, Pharmacology Biochemistry and Behavior.

[14]  David Silbersweig,et al.  SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder , 2000, Biological Psychiatry.

[15]  C. Piérard,et al.  Effects of GABA-transaminase inhibition on brain metabolism and amino-acid compartmentation: an in vivo study by 2D 1H-NMR spectroscopy coupled with microdialysis , 1999, Experimental Brain Research.

[16]  H. Silfvenius,et al.  Proton magnetic resonance spectroscopy of brain biopsies from patients with intractable epilepsy , 1999, Epilepsy Research.

[17]  D L Rothman,et al.  Acute Effects of Vigabatrin on Brain GABA and Homocarnosine in Patients with Complex Partial Seizures , 1999, Epilepsia.

[18]  M. McCarthy,et al.  Developmental sex differences in amino acid neurotransmitter levels in hypothalamic and limbic areas of rat brain , 1999, Neuroscience.

[19]  D L Rothman,et al.  Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. , 1999, The American journal of psychiatry.

[20]  T Ernst,et al.  Gender effects on persistent cerebral metabolite changes in the frontal lobes of abstinent cocaine users. , 1999, The American journal of psychiatry.

[21]  L. Barré,et al.  Relationships between trait and state anxiety and the central benzodiazepine receptor: a PET study , 1999, The European journal of neuroscience.

[22]  N. Volkow,et al.  A novel strategy for the treatment of cocaine addiction , 1998, Synapse.

[23]  V J Cunningham,et al.  Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. , 1998, Archives of general psychiatry.

[24]  Jullie W Pan,et al.  Topiramate increases cerebral GABA in healthy humans , 1998, Neurology.

[25]  W. Ling,et al.  Baclofen as a Cocaine Anti-Craving Medication: A Preliminary Clinical Study , 1998, Neuropsychopharmacology.

[26]  Jullie W Pan,et al.  Measurements of human cerebral GABA at 4.1 T using numerically optimized editing pulses , 1998, Magnetic resonance in medicine.

[27]  S. Dewey,et al.  Effects of pharmacologic increases in brain GABA levels on cocaine‐induced changes in extracellular dopamine , 1998, Synapse.

[28]  Linda Chang,et al.  Neurochemical alterations in asymptomatic abstinent cocaine users: A proton magnetic resonance spectroscopy study , 1997, Biological Psychiatry.

[29]  Jullie W Pan,et al.  Biological and clinical MRS at ultra‐high field , 1997, NMR in biomedicine.

[30]  J S Fowler,et al.  Regional brain metabolic response to lorazepam in alcoholics during early and late alcohol detoxification. , 1997, Alcoholism, clinical and experimental research.

[31]  S. J. Gatley,et al.  Relationship between subjective effects of cocaine and dopamine transporter occupancy , 1997, Nature.

[32]  P F Renshaw,et al.  In vivo detection of GABA in human brain using a localized double‐quantum filter technique , 1997, Magnetic resonance in medicine.

[33]  R. Mattson,et al.  Human brain GABA levels rise rapidly after initiation of vigabatrin therapy , 1996, Neurology.

[34]  R. Mattson,et al.  Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose , 1996, Neurology.

[35]  B. Adinoff,et al.  Levels of gamma-aminobutyric acid in cerebrospinal fluid and plasma during alcohol withdrawal , 1995, Psychiatry Research.

[36]  A H Wilman,et al.  Yield enhancement of a double-quantum filter sequence designed for the edited detection of GABA. , 1995, Journal of magnetic resonance. Series B.

[37]  W. Kaschka,et al.  Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. , 1995, Journal of psychiatric research.

[38]  T. Richards,et al.  Proton magnetic resonance spectroscopy investigation of hyperventilation in subjects with panic disorder and comparison subjects. , 1995, The American journal of psychiatry.

[39]  A. Pitkänen,et al.  Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder , 1995, Nuclear medicine communications.

[40]  R. Mattson,et al.  Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Fink-Jensen,et al.  The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. , 1992, European journal of pharmacology.

[42]  E. G. Jones,et al.  Numbers and proportions of GABA-immunoreactive neurons in different areas of monkey cerebral cortex , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  F. Petty,et al.  Plasma GABA levels in chronic alcoholics. , 1985, The American journal of psychiatry.

[44]  J. Tallman,et al.  GABAergic modulation of benzodiazepine binding site sensitivity , 1978, Nature.

[45]  C. Marsden.  GABA in Nervous System Function , 1977 .

[46]  A. Bockisch,et al.  Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[47]  S. Dager,et al.  Brain metabolic changes during lactate‐induced panic: Effects of gabapentin treatment , 2001, Depression and anxiety.

[48]  T. Smith,et al.  Type A gamma-aminobutyric acid (GABAA) receptor subunits and benzodiazepine binding: significance to clinical syndromes and their treatment. , 2001, British journal of biomedical science.

[49]  R. Mattson,et al.  GABA and the ornithine delta-aminotransferase gene in vigabatrin-associated visual field defects. , 2001, Seizure.

[50]  G. Gessa,et al.  Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence. , 2000, Alcoholism, clinical and experimental research.

[51]  J. Krystal,et al.  Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. , 2000, Critical reviews in neurobiology.

[52]  M. Floeter,et al.  The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. , 1999, Annals of internal medicine.

[53]  S. Posse,et al.  Two-dimensional proton echo-planar spectroscopic imaging of brain metabolic changes during lactate-induced panic. , 1999, Archives of general psychiatry.

[54]  Tomkins Dm,et al.  Evidence that GABA(A) but not GABA(B) receptor activation in the dorsal raphe nucleus modulates ethanol intake in Wistar rats. , 1996 .

[55]  B. Scatton,et al.  The GABA hypothesis of depression and antidepressant drug action. , 1985, Psychopharmacology bulletin.